AS2 Bio

Executive Summary

AS2 Bio is a privately held biotechnology company founded in 2021 and based in Cambridge, Massachusetts, dedicated to developing targeted protein degradation therapies for Angelman syndrome and other diseases. The company leverages a multi-modal approach combining molecular glues and PROTACs to address the underlying genetic cause of this rare neurodevelopmental disorder. By targeting the UBE3A protein pathway, AS2 Bio aims to restore normal protein function, offering a potentially disease-modifying treatment for patients who currently have no approved therapies. With a strong scientific foundation and a clear focus on Angelman syndrome, the company is positioned to advance its lead candidates through preclinical development and into clinical trials. While still in early stages, AS2 Bio's innovative platform could have broader applications beyond Angelman syndrome, making it an attractive opportunity in the targeted protein degradation space.

Upcoming Catalysts (preview)

• Q1 2027Lead candidate nomination for Angelman syndrome program60% success
• Q3 2026Preclinical efficacy data presentation at a major conference70% success
• Q4 2026IND-enabling studies initiation50% success